Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|November 30, 2016
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant OrganismsElizabeth Temkin, Julian Torre-Cisneros, Bojana Beovic, et al.
Journal of Global Antimicrobial Resistance|November 17, 2021
Association between rectal colonisation by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae and mortality: a prospective, observational studyÁngela Cano, Belén Gutiérrez-Gutiérrez, Isabel Machuca, et al.
The Lancet Regional Health. Europe|April 14, 2025
Safety and efficacy of immunoguided prophylaxis for cytomegalovirus disease in low-risk lung transplant recipients in Spain: a multicentre, open-label, randomised, phase 3, noninferiority trialAurora Páez-Vega, José M Vaquero-Barrios, Elisa Ruiz-Arabi, et al.
Antimicrobial Resistance and Infection Control|August 7, 2025
Incidence, clinical and genomic trends of hospital- and Non-hospital-onset KPC-producing Klebsiella pneumoniae infections before and during the COVID-19 era: a ten-year interrupted time series studyManuel Recio-Rufián, Teresa López-Viñau, Víctor Gálvez-Soto, et al.
Mayo Clinic Proceedings|October 8, 2016
A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing EnterobacteriaceaeBelén Gutiérrez-Gutiérrez, Elena Salamanca, Marina de Cueto, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|August 7, 2024
How can we optimize the diagnostic and therapeutic approach to pneumonia? Expert opinion-based recommendationsMario Fernández-Ruiz, Juan José Castón, José Luis Del Pozo, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2021
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Infectious Diseases and Therapy|May 25, 2022
Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Pageof 6